home / stock / rain / rain news

RAIN News and Press, Rain Therapeutics Inc. From 05/11/23

Stock Information
Company Name: Rain Therapeutics Inc.
Stock Symbol: RAIN
Market: NASDAQ
Website: rainthera.com
Menu
RAIN RAIN Quote RAIN Short RAIN News RAIN Articles RAIN Message Board
Get RAIN Alerts

News, Short Squeeze, Breakout and More Instantly...
RAIN - Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress

– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial – – Required...
RAIN - Rain Oncology to Report First Quarter 2023 Financial Results and Highlights Recent Progress on May 11, 2023

NEWARK, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that ...

RAIN - Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023

NEWARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates ...

RAIN - Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress

NEWARK, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates ...
RAIN - SVRA and CYTO among healthcare gainers

2023-03-10 11:41:50 ET Gainers: Euda Health ( EUDA ) +53% . Unicycive ( UNCY ) +27% . Tenon Medical ( TNON ) +12% . Rain ( RAIN ) +11% . Altamira ( CYTO ) +11% . Losers: Meihua International ( MHUA ) -34% . Fr...

RAIN - Rain Oncology Inc. (RAIN) Q4 2022 Earnings Call Transcript

2023-03-09 21:04:08 ET Rain Oncology Inc. (RAIN) Q4 2022 Results Conference Call March 09, 2023 05:00 PM ET Company Participants Dan Ferry - LifeSci Advisors Avanish Vellanki - Chief Executive Officer Robert Doebele - Chief Scientific Officer Richard Bryce - ...

RAIN - Rain Therapeutics GAAP EPS of $0.70

2023-03-09 16:30:46 ET Rain Therapeutics press release ( NASDAQ: RAIN ): Q4 GAAP EPS of $0.70. Cash, cash equivalents and short-term investments of $130.45M, vs. 140.22M a year ago. Shares -0.47% AH. For further details see: Rain Therapeutics GAAP EPS of ...
RAIN - Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

– Year-end cash position of $130.5 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial – – Topline d...

RAIN - Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference

NEWARK, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates ...

RAIN - Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 2023

NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that r...
Previous 10 Next 10